TheEdgeResearch
Home / Stocks / PTE

PolarityTE, Inc. (PTE)

NASDAQ Healthcare Biotechnology
$0.24 ▼ -0.82%
Market Cap
$1.8M
Sector
Healthcare
Industry
Biotechnology
Beta
1.15
52-Wk Range
—
CEO
Richard Hague
Country
US
Currency
USD

PolarityTE, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Salt Lake City, UT, US. The stock last traded at $0.24, down 0.82% on the session, giving a market capitalisation of $1.8M. On trailing twelve-month figures it carries a trailing P/E of 0.16, a net margin of 1254.4%. Its beta of 1.15 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
0.16
Price / Sales
2.18
Price / Book
0.10
EV / EBITDA
1.00
Gross margin
24.3%
Operating margin
-3179.0%
Net margin
1254.4%
Return on equity
—
Debt / equity
0.20
Current ratio
6.41
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
42
IPO date
1999-08-16
Headquarters
Salt Lake City, UT, US
About PolarityTE, Inc.

Based in Salt Lake City, Utah, PolarityTE, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of regenerative tissue products and biomaterials. Its offerings serve the medical, biomedical engineering, and material sciences sectors across the United States. The company operates through two primary divisions: Regenerative Medicine Products and Contract Services. PolarityTE's key product is SkinTE, a specialized tissue solution employed for the repair, reconstruction, replacement, or augmentation of skin in patients. Its applications encompass treating acute or chronic wounds, burns, surgical reconstruction, scar revision, and the removal of dysfunctional skin grafts. In addition to its product line, the firm also provides contract research services. The company's pipeline includes SkinTE Cryo, which facilitates multiple deployments from a single harvest through a cryopreservation process, and a SkinTE point-of-care device designed for immediate processing and application of SkinTE directly after initial harvest. PolarityTE is also advancing PTE 11000, an allogenic, biologically active dressing engineered to accelerate healing in both wound care and aesthetic contexts, alongside other promising tissue regeneration products.

Comparable companies

PolarityTE, Inc. is most often compared with the following Healthcare names:

ASLNFRESGMVDMTPNBSENTBLONCSQONCTTMBRVBIV
More research on PTE
PTE technical analysis PTE TheEdge Score Compare against peers
Open full interactive analysis & DCF →